Reversible cutaneous lymphoma occurring during methotrexate therapy

Viraben, R.; Brousse, Paul; Lamant, Laurence

doi:10.1111/j.1365-2133.1996.tb03621.x

Cited by 43 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A variety of cutaneous complications of methotrexate therapy have been described including a papular eruption, cutaneous mucinous nodules, accelerated formation of rheumatoid nodules, vasculitis, ulceration, cutaneous lymphoma and pseudolymphoma. 12–18 None of these processes has histopathological changes similar to those we have described.…”

Section: Discussionmentioning

confidence: 51%

Cutaneous histiocytic lymphangitis: An unusual manifestation of rheumatoid arthritis

et al. 2000

View full text Add to dashboard Cite

Two cases are presented of unusual cutaneous lesions associated with rheumatoid arthritis in underlying joints. The lesions were evanescent, erythematous and violaceous partly macular and partly indurated plaques, with a livedo-like pattern of erythema at the edge in one case. Histological changes were identical in the two cases. The major features were dilated, dermal lymphatics containing aggregates of inflammatory cells, mainly histiocytes, with adjacent perivascular lymphoid aggregates. An appropriate name for this reaction would appear to be cutaneous histiocytic lymphangitis.

show abstract

Section: Discussionmentioning

confidence: 51%

Cutaneous histiocytic lymphangitis: An unusual manifestation of rheumatoid arthritis

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Forty per cent of these have extra‐nodal involvement. Ten cases of methotrexate‐associated primary cutaneous lymphomas have been described . The majority of these tumours are of B‐cell origin with half being EBV‐positive.…”

Section: Resultsmentioning

confidence: 99%

“…A 3‐fold increased risk of malignant melanoma has been described in methotrexate‐exposed rheumatology patients . A number of case reports have underlined this association . As no data are available in the IBD literature, it could be potentially hazardous to extrapolate this risk from rheumatology to IBD subjects.…”

Section: Resultsmentioning

confidence: 99%

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Moran

Lim

Bailey

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background With the expanding list of medications available to treat patients with inflammatory bowel disease (IBD), it is important to recognise adverse events, including those involving the skin. Dermatological adverse events may be confused with extra‐intestinal manifestations of IBD. Aim To review drug‐related dermatological manifestations associated with immunosuppressive and anti‐tumour necrosis factor (anti‐TNF) therapy. Methods The literature was searched on PubMed for dermatological adverse events in IBD. Results Present thiopurine exposure was associated with a 5.9‐fold [95% confidence interval (CI), 2.1–16.4] increased risk of developing non‐melanoma skin cancer (NMSC). The peak incidence is highest in Caucasians over the age of 65 years with crude incidence rates of 4.0 and 5.7/1000 patient‐years for present and previous use. In anti‐TNF‐exposed subjects, drug‐induced lupus was reported in 1% of the cases and a psoriatic rash in up to 3% of the cases. Anti‐TNF monotherapy increases the risk of NMSC ~2‐fold to a rate of 0.5 cases per 1000 person‐years. Cutaneous lymphomas have been rarely reported in subjects on thiopurine or anti‐TNF drug monotherapy. Combination therapy seems to have an additive effect on the risk of developing NMSC and lymphoma. Conclusions Physicians need to be aware of the wide spectrum of dermatological complications of immunosuppressive and anti‐TNF therapy in IBD, especially psoriasis and non‐melanoma skin cancer. Vigilance and regular screening for non‐melanoma skin cancer is recommended. Case discussions between gastroenterologists and dermatologists should be undertaken to best manage dermatological adverse events.

show abstract

“…Epstein-Barr virus (EBV) has been pathogenetically implicated based on the higher incidence of primary or reactivated EBV infection in patients with PTLD compared with the general transplant population, a high level of EBV DNA in the blood of affected patients and the detection of EBV protein, DNA or RNA in the majority of biopsies of PTLD. [5][6][7][8][9][10] Only in a minority of cases does PTLD first manifest in the skin. The categories of cutaneous PTLD are no different than extracutaneous PTLD and include reactive plasmacytic hyperplasia, polymorphic PTLD, monomorphic B-cell PTLD and T-cell neoplasms.…”

mentioning

confidence: 99%

Post‐transplant EBV‐negative anaplastic large‐cell lymphoma with dual rearrangement: a propos of two cases and review of the literature

et al. 2007

View full text Add to dashboard Cite

show abstract

Reversible cutaneous lymphoma occurring during methotrexate therapy

Cited by 43 publications

References 7 publications

Cutaneous histiocytic lymphangitis: An unusual manifestation of rheumatoid arthritis

Cutaneous histiocytic lymphangitis: An unusual manifestation of rheumatoid arthritis

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease

Post‐transplant EBV‐negative anaplastic large‐cell lymphoma with dual rearrangement: a propos of two cases and review of the literature

Contact Info

Product

Resources

About